证券代码：430300 证券简称：辰光医疗 公告编号：2025-106 上海辰光医疗科技股份有限公司 关于使用自有资金支付募投项目人员费用 并以募集资金等额置换的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 二、 募集资金投资项目情况 2024 年 8 月 25 日，公司召开第五届董事会第十二次会议、第五届监事会第 七次会议，分别审议通过《关于变更募集资金用途的议案》，公司拟将"磁共振 成像核心零部件研发及产业化项目"项目的剩余募集资金中的 2,831.84 万元的 用于"磁共振系统集成研发产业化及营销升级项目"，实施主体不变。公司于 2024 年 9 月 13 日召开 2024 年第二次临时股东会审议通过上述议案。公司保荐机构和 独立董事对上述事项无异议。具体内容详见 2024 年 8 月 27 日，公司在北京证券 交易所指定信息披露平台（www.bse.cn）披露的《变更募集资金用途公告》（公 告编号：2024-073）。 公司变更后的募集资金投资项目具体情况如下： 单位：元 | 序 | 项 ...

2.会议召开地点：上海市青浦区华青路 1269 号 证券代码：430300 证券简称：辰光医疗 公告编号：2025-105 上海辰光医疗科技股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 9 月 8 日 3.会议召开方式：现场会议 4.发出董事会会议通知的时间和方式：2025 年 9 月 3 日以书面、电话和微信 方式发出 5.会议主持人：董事长 王杰先生 6.会议列席人员：高级管理人员 7.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律、行政法规、规范性文件和《公 司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于使用自有资金支付募投项目人员费用并以募集资金等额置 换的议案》 1.议案内容： 3.回避表决情况： 本议案不涉及回避表决。 4.提交股东会表决情况： 本议案无需 ...

Core Insights - A new iron-based superconducting wire material has been developed by researchers at the Chinese Academy of Sciences, achieving record performance metrics [1] - Superconducting concept stocks have seen an average increase of 34.1% this year, with seven stocks rising over 50% [1] - Ten superconducting concept stocks have received "positive" ratings from five or more institutions, with Zhongtian Technology being the most favored [1] Stock Performance - Zhongtian Technology has a market capitalization of 55.6 billion yuan and a rolling P/E ratio of 18.87, receiving ratings from 19 institutions [4] - Xibu Superconductor has a market capitalization of 39.3 billion yuan and a rolling P/E ratio of 39.37, with ratings from 16 institutions [4] - Other notable stocks include: - Zhongfu Industrial: 20.5 billion yuan market cap, P/E ratio of 21.20, 9 ratings [4] - Zhongtung High-tech: 43.9 billion yuan market cap, P/E ratio of 33.71, 9 ratings [4] - Guoda Special Materials: 7.6 billion yuan market cap, P/E ratio of 29.66, 8 ratings [4] Profit Growth Expectations - Five stocks among those with significant institutional interest are expected to have net profit growth exceeding 20% over the next two years, including Guoda Special Materials, Zhongfu Industrial, Lianchuang Optoelectronics, Dongfang Tantalum, and Xibu Superconductor [1]

Market Performance - The North Exchange 50 Index reached a historical high of 1618.18 points on September 5, with a 5.15% increase and a trading volume of 44.059 billion yuan [1] - The index experienced a weekly increase of 2.79%, indicating a recovery in market confidence and trading enthusiasm [1] Investor Sentiment - Market sentiment is high, driven by strong individual stock performances, attracting short-term capital [2] - Five companies on the North Exchange hit the 30% daily limit up on September 5, although one popular stock, Hongyu Packaging, experienced significant volatility with a 21.33% trading range and a 4.18% drop on Friday [2] Future Outlook - Analysts expect the North Exchange to maintain a positive outlook for September, supported by index sample adjustments, code switches, and the launch of specialized funds [3] - The public fund's holdings in North Exchange stocks reached a historical high of 0.32% of total market value in Q2, indicating potential for further capital inflow [2] Sector Performance - The automotive sector showed strong growth, with a 23.63% increase in net profit for companies in the North Exchange during the first half of the year, driven by policy support and structural upgrades [4] - The high-end equipment manufacturing sector also performed well, with a 15.95% increase in net profit, highlighting the industry's stability [5] R&D Investment - North Exchange companies collectively invested 4.139 billion yuan in R&D in the first half of the year, a 2.59% increase year-on-year, with significant investments in information technology and biomedicine [6] - Several companies are focusing on core technology advancements, such as Tian Gong Co. promoting the domestic production of high-end titanium materials and Chuangyuan Xinke actively developing 6G technology [6]

Core Insights - The Beijing Stock Exchange (BSE) has seen steady growth in market size and quality, with 274 listed companies and a total market capitalization exceeding 900 billion yuan as of September 3, 2025 [2] - Over 60% of BSE-listed companies reported revenue growth in the first half of 2025, with a profitability rate of 82.12% [2][6] - The BSE 50 Index has experienced a remarkable increase of 49.49% in 2025, outperforming other major indices [2][3] Market Performance - The BSE has shown a significant recovery, with average daily trading volume reaching 296.25 billion yuan in the first half of 2025 [3] - The number of companies with market capitalization exceeding 100 billion yuan has increased by 5, while those between 50 billion and 100 billion yuan have increased by 20 [3] - 60 companies have seen their stock prices double this year, with notable performers including Xingtu Measurement Control, Guangxin Technology, and Tiangong Co., whose stock prices increased by 1347%, 795%, and 413% respectively [3] Financial Health - BSE-listed companies achieved a total revenue of 920.64 billion yuan in the first half of 2025, reflecting a year-on-year growth of 6.01% [6] - The average net profit for these companies was 59.09 billion yuan, with a decline of 10.59% year-on-year, indicating a narrowing of losses [6] - The second quarter of 2025 showed signs of recovery, with revenues of 505.47 billion yuan, a quarter-on-quarter increase of 21.75% [6] Research and Development - BSE-listed companies increased their R&D spending to 41.39 billion yuan in the first half of 2025, a growth of 2.59% year-on-year [7] - Companies in the information technology and biomedicine sectors are leading in R&D investment intensity, with some firms allocating over 30% of their revenue to R&D [7] Future Expectations - The BSE is expected to continue its reform efforts, focusing on improving liquidity, optimizing listing pathways, and enhancing investor structure [9] - There is a strong anticipation for the introduction of BSE ETFs to increase market liquidity and provide investment channels for retail investors [9] - The BSE aims to maintain its position as a core platform for innovative small and medium-sized enterprises, fostering the growth of high-tech companies [9][10]

Overall Performance - In the first half of 2025, companies listed on the Beijing Stock Exchange achieved a total operating income of 92.064 billion yuan, with an average operating income of 336 million yuan, reflecting a year-on-year growth of 6.01% [2] - The total net profit attributable to shareholders was 5.909 billion yuan, with an average net profit of 21.5646 million yuan, showing a decline of 10.59%, although the decline rate has narrowed [2] - Over 60% of companies reported revenue growth, with 225 companies profitable, resulting in a profitability rate of 82.12% [2] - In Q2, companies reported a total operating income of 50.547 billion yuan, a quarter-on-quarter increase of 21.75%, and a net profit of 3.133 billion yuan, up 12.88% from the previous quarter [2] Industry Highlights - The automotive industry showed strong performance, with net profit growth of 23.63% in the first half of the year, driven by policies promoting vehicle upgrades [3] - Companies in the beauty and textile sectors also benefited from consumer trends, with net profit growth of 26.12% and 42.91%, respectively [3] - The equipment manufacturing sector maintained rapid growth, with net profit increasing by 15.95% [3] R&D Investment - Companies on the Beijing Stock Exchange increased R&D spending to 4.139 billion yuan, a year-on-year increase of 2.59%, with significant investments in information technology and biomedicine [4] - Eight companies had R&D expenditures exceeding 30% of their operating income, while four companies invested over 100 million yuan in R&D [4] - A total of 72 companies implemented equity incentive plans, covering 4,266 individuals, to attract and retain talent [4] Financing and M&A Activities - In 2025, 12 companies raised a total of 3.856 billion yuan through public offerings, while five companies announced targeted convertible bond issuances totaling 704 million yuan [5] - Eleven companies disclosed cash asset purchase announcements, with a total transaction amount of 2.650 billion yuan [6] - Significant mergers and acquisitions were noted, such as Xujie Technology's acquisition of a stake in a downstream photovoltaic power station investment and operation company [6] Investor Relations and Market Performance - Approximately 70% of listed companies implemented cash dividends, totaling 4.974 billion yuan, an increase of 5.35% year-on-year [7] - The number of qualified investors reached 8.6613 million, an increase of 675,600 from the previous year, with daily average trading participation of 343,700 investors [8] - The average daily trading volume was 29.625 billion yuan, with the market showing a positive trend following the launch of the Beijing Stock Exchange Specialized Index [8]

Group 1: Overall Performance - In the first half of 2025, companies listed on the Beijing Stock Exchange demonstrated resilience and growth potential, with total operating revenue reaching 92.064 billion yuan, an increase of 6.01% year-on-year [1] - The net profit attributable to shareholders was 5.909 billion yuan, with an average net profit of 21.5646 million yuan per company, reflecting a year-on-year decline of 10.59%, but the decline has narrowed compared to previous years [1] - Over 60% of companies reported revenue growth, with 225 companies profitable, resulting in a profitability rate of 82.12% [1] Group 2: Sector Highlights - The consumer sector showed policy-driven growth, particularly in the automotive industry, where companies like Kaitie achieved approximately 40% growth in both revenue and net profit [2] - The beauty and textile industries also thrived, with companies like Taihu Snow reporting a net profit increase of 69.77% [2] - Equipment manufacturing maintained rapid growth, exemplified by Wantong Hydraulic's net profit growth of 40.33% [2] Group 3: Innovation and Investment - Companies increased R&D investment, totaling 4.139 billion yuan, a year-on-year increase of 2.59%, with leading sectors being information technology and biomedicine [3] - Twelve companies completed public financing totaling 3.856 billion yuan, and five companies planned to issue a total of 704 million yuan in targeted convertible bonds [3] - Eleven companies disclosed cash acquisitions totaling 2.650 billion yuan, indicating active mergers and acquisitions for industry integration and transformation [3]

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Group 1 - The core point of the article is the significant block trade of Chen Guang Medical on August 29, involving a volume of 232,000 shares and a transaction amount of 3.944 million yuan, with a transaction price of 17.00 yuan, reflecting a premium of 0.29% over the closing price of the day [2][3] - The buyer of the block trade was Changjiang Securities Co., Ltd. Beijing Million Zhuang Street Securities Business Department, while the seller was Changjiang Securities Co., Ltd. Wuhan Luoyu Road Securities Business Department [2] - On the same day, Chen Guang Medical's closing price was 16.95 yuan, showing a decline of 0.53%, with a turnover rate of 2.93% and a total transaction amount of 33.4491 million yuan, indicating a cumulative decline of 3.31% over the past five days [2]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-102 上海辰光医疗科技股份有限公司 关联交易公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 公司拟向中信银行股份有限公司上海分行申请并使用人民币 1,000 万元的 综合授信，期限为 12 个月，用于补充流动资金。控股股东及实际控制人王杰提 供连带责任保证担保。 在实际贷款业务发生时，具体授信事宜以中信银行相关协议为准。 董事会授权公司董事长王杰先生代表本公司办理上述信贷事宜并签署有关 合同和文件。 （二）决策与审议程序 本次关联交易经公司第五届董事会第二十一次会议审议通过，并已按照《公 司章程》相关规定王杰先生及左永生先生执行了回避表决，本议案尚需提交公司 2025 年第二次临时股东会审议。 上述议案已经公司第五届董事会独立董事专门会议审议通过，独立董事一致 同意并将该议案提交董事会审议。 （三）本次关联交易不存在需经有关部门批准的情况 二、关联方基本情况 1. 自然人 姓名：王杰 住所：上海 ...